Delving into the Latest Updates on RLT-001 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

NNMT

Mechanism

NNMT inhibitors(Nicotinamide N methyltransferase inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2Obesity

Originator Organization

Ridgeline TherapeuticsStartup

Active Organization-

Inactive Organization

Ridgeline TherapeuticsStartup

Drug Highest PhaseDiscontinuedPreclinical

First Approval Date-

Regulation-

A chronic debilitating parasitic infection, viscerotropic leishmaniasis (VTL), has been described in Operation Desert Storm veterans. Diagnosis of this disease, caused by Leishmania tropica, has been difficult due to low or absent specific immune responses in traditional assays. We report the cloning and characterization of two genomic fragments encoding portions of a single 210-kDa L. tropica protein useful for the diagnosis of VTL in U.S. military personnel. The recombinant proteins encoded by these fragments, recombinant (r) Lt-1 and rLt-2, contain a 33-amino acid repeat that reacts with sera from Desert Storm VTL patients and with sera from L. tropica-infected patients with cutaneous leishmaniasis. Antibody reactivities to rLt-1 indicated a bias toward IgG2 in VTL patient sera. Peripheral blood mononuclear cells from VTL patients produced interferon gamma, but not interleukin 4 or 10, in response to rLt-1. No cytokine production was observed in response to parasite lysate. The results indicate that specific leishmanial antigens may be used to detect immune responses in VTL patients with chronic infections.

100 Deals associated with RLT-001

Login to view more data